Short answer · Medically reviewed summary · Last updated: 2026-05-08
Pyoderma gangrenosum was first described by Louis Brocq in 1916 as "phagedenism geometrique," though it was formally named pyoderma gangrenosum by Brunsting, Goeckerman, and O'Leary at the Mayo Clinic in 1930. Originally misidentified as an infectious process, medical understanding has evolved to recognize it as a rare, non-infectious, neutrophilic dermatosis often associated with systemic inflammatory conditions. When was Pyoderma Gangrenosum first identified? While French dermatologist Louis Brocq first noted the condition in 1916, the 1930 report by the Mayo Clinic team remains the defining moment in the history of pyoderma gangrenosum.
What is the history of Pyoderma Gangrenosum?
History of Pyoderma Gangrenosum: when and how it was discovered, and the milestones in research since, medically reviewed.
Pyoderma gangrenosum was first described by Louis Brocq in 1916 as "phagedenism geometrique," though it was formally named pyoderma gangrenosum by Brunsting, Goeckerman, and O'Leary at the Mayo Clinic in 1930. Originally misidentified as an infectious process, medical understanding has evolved to recognize it as a rare, non-infectious, neutrophilic dermatosis often associated with systemic inflammatory conditions.
When was Pyoderma Gangrenosum first identified?
While French dermatologist Louis Brocq first noted the condition in 1916, the 1930 report by the Mayo Clinic team remains the defining moment in the history of pyoderma gangrenosum. Early clinicians mistakenly believed the rapidly expanding, necrotic ulcers were caused by bacterial infections, leading to aggressive surgical debridement that unfortunately worsened the condition through a phenomenon known as pathergy—where skin trauma triggers further ulceration.
How has our understanding of Pyoderma Gangrenosum evolved?
Over the last century, the medical community shifted its perspective from viewing pyoderma gangrenosum as an infectious disease to recognizing it as an autoinflammatory disorder. We now know that approximately 50% of patients with pyoderma gangrenosum have an underlying systemic disease, most commonly inflammatory bowel disease (IBD), rheumatoid arthritis, or hematologic malignancies.
What are the major milestones in treatment?
The management of pyoderma gangrenosum has transformed significantly as we moved away from invasive surgery toward systemic immunosuppression:
- 1950s: Introduction of systemic corticosteroids as the first-line therapy.
- 1980s: Adoption of cyclosporine and other immunosuppressants to manage recalcitrant cases.
- 2000s-Present: Integration of biologic therapies, such as TNF-alpha inhibitors, which target specific inflammatory pathways.
How has patient advocacy changed the landscape?
Historically, patients with pyoderma gangrenosum suffered in isolation due to the rarity of the disease and its often-misunderstood nature. Today, platforms like DiseaseMaps.org provide a vital space for the 39 members of our community to connect, share treatment experiences, and advocate for research, helping to reduce the diagnostic delay that many patients previously faced.
Next steps
- Consult a dermatologist or rheumatologist specializing in neutrophilic dermatoses.
- Join our community at DiseaseMaps.org to connect with others who have been diagnosed with pyoderma gangrenosum.
- Keep a detailed log of your symptoms and potential triggers to share during your clinical consultations.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Pyoderma gangrenosum overview.
- Orphanet: Rare disease database entry for pyoderma gangrenosum.
- PubMed: Historical review of neutrophilic dermatoses and the evolution of immunomodulatory therapy.
- The Mayo Clinic: Historical archives on the initial classification of pyoderma gangrenosum.
